Market Overview

Piper Jaffray Maintains Overweight on Arena Pharmaceuticals on Share Rally

Share:
Related ARNA
Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research
Jefferies: 10 Buyout Targets To Own During The M&A Boom
Orexigen: Contrave Sales Pop, Equity Response Muted (Seeking Alpha)

Piper Jaffray has published a research report on Arena Pharmaceuticals (NASDAQ: ARNA) commenting on the stock's 27% rise this week to date.

In the report, Piper Jaffray writes, "Shares of ARNA have risen 27% this week ahead of the company's June 27th PDUFA date for obesity drug Lorcaserin. We believe a lot of the volume has been driven by retail investors. Arena is one of the most heavily shorted stocks in our coverage universe with a ~22% short interest, so we could be seeing a squeeze. We maintain our Overweight rating pending the outcome of the June 27th PDUFA date, which will likely impact our current $7 price target."

Piper Jaffray maintains its Overweight rating and $7 price target on Arena Pharmaceuticals, which is currently trading down ~3.30% from yesterday's $7.88 closing price.

Latest Ratings for ARNA

DateFirmActionFromTo
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & CompanyInitiates Coverage onMarket Perform
Oct 2013Piper JaffrayMaintainsOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ARNA)

Around the Web, We're Loving...